Batoprotafib

Overview

Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 ( IC 50 =0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.

Application

Products | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > SHP2 | Products > Signaling Pathways > Phosphatase

Product Information

• Catalog No.: HY-136173
• CAS No.: 1801765-04-7
• Molecular Formula: C18H24ClN7OS
• Molecular Weight: 421.95
• Purity: 99.89%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution
• Availability: In-stock

Source

Original product source